Incyte (INCY) Stock Forecast, Price Target & Predictions
INCY Stock Forecast
Incyte stock forecast is as follows: an average price target of $81.00 (represents a 27.44% upside from INCY’s last price of $63.56) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
INCY Price Target
The average price target for Incyte (INCY) is $81.00 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $136.00 to $48.00. This represents a potential 27.44% upside from INCY's last price of $63.56.
INCY Analyst Ratings
According to 17 Wall Street analysts, Incyte's rating consensus is 'Buy'. The analyst rating breakdown for INCY stock is 0 'Strong Buy' (0.00%), 10 'Buy' (58.82%), 7 'Hold' (41.18%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Incyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 18, 2024 | David Lebowitz | Citigroup | $92.00 | $62.16 | 48.01% | 44.75% |
| Jul 31, 2024 | Brian Abrahams | RBC Capital | $66.00 | $65.70 | 0.46% | 3.84% |
| Jul 26, 2024 | Jay Olson | Oppenheimer | $81.00 | $68.57 | 18.13% | 27.44% |
| Jul 02, 2024 | Evan Seigerman | BMO Capital | $48.00 | $60.87 | -21.14% | -24.48% |
| May 23, 2024 | James Shin | Deutsche Bank | $55.00 | $58.20 | -5.50% | -13.47% |
| Apr 30, 2024 | Evan David Seigerman | BMO Capital | $52.00 | $52.05 | -0.10% | -18.19% |
| Apr 25, 2024 | Jasper Hellweg | Argus Research | $70.00 | $50.48 | 38.67% | 10.13% |
| Feb 08, 2023 | - | Cowen & Co. | $100.00 | $80.38 | 24.42% | 57.33% |
| Jan 03, 2023 | - | Wells Fargo | $75.00 | $79.73 | -5.94% | 18.00% |
| Aug 15, 2022 | Jay Olson | Oppenheimer | $98.00 | $73.99 | 32.45% | 54.19% |
The latest Incyte stock forecast, released on Aug 18, 2024 by David Lebowitz from Citigroup, set a price target of $92.00, which represents a 48.01% increase from the stock price at the time of the forecast ($62.16), and a 44.75% increase from INCY last price ($63.56).
Incyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 4 | 7 |
| Avg Price Target | $92.00 | $71.75 | $66.29 |
| Last Closing Price | $63.56 | $63.56 | $63.56 |
| Upside/Downside | 44.75% | 12.89% | 4.30% |
In the current month, the average price target of Incyte stock is $92.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 44.75% increase as opposed to Incyte's last price of $63.56. This month's average price target is up 28.22% compared to last quarter, and up 38.78% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 15, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Jul 31, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 31, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jul 31, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 26, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 02, 2024 | BMO Capital | Market Perform | Underperform | Downgrade |
| Jun 18, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
| May 23, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
| May 23, 2024 | Oppenheimer | Underperform | Underperform | Hold |
Incyte's last stock rating was published by RBC Capital on Sep 03, 2024. The company gave INCY a "Sector Perform" rating, the same as its previous rate.
Incyte Financial Forecast
Incyte Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $919.02M | $954.61M | $808.67M | $926.70M | $823.30M | $911.40M | $733.24M | $862.85M | $812.99M | $705.71M | $604.72M | $789.51M | $620.64M | $688.04M | $568.51M | $579.39M | $551.58M |
| Avg Forecast | $1.39B | $1.33B | $1.26B | $1.10B | $1.20B | $1.15B | $1.13B | $999.87M | $1.14B | $1.08B | $1.01B | $921.89M | $1.00B | $963.63M | $909.68M | $859.17M | $878.25M | $842.66M | $818.49M | $749.98M | $812.44M | $746.09M | $685.41M | $659.08M | $660.12M | $622.63M | $608.32M | $556.06M | $575.04M | $534.94M |
| High Forecast | $1.41B | $1.35B | $1.28B | $1.11B | $1.21B | $1.16B | $1.14B | $1.01B | $1.15B | $1.16B | $1.03B | $931.84M | $1.04B | $999.01M | $919.49M | $868.43M | $887.73M | $851.75M | $853.12M | $781.71M | $846.81M | $777.65M | $714.40M | $686.96M | $688.04M | $648.97M | $634.05M | $579.58M | $599.37M | $557.57M |
| Low Forecast | $1.37B | $1.31B | $1.24B | $1.08B | $1.18B | $1.13B | $1.11B | $981.64M | $1.11B | $1.06B | $996.35M | $905.09M | $971.32M | $941.00M | $893.10M | $843.51M | $862.25M | $827.30M | $799.75M | $732.80M | $793.83M | $729.00M | $669.71M | $643.98M | $645.00M | $608.37M | $594.39M | $543.32M | $561.87M | $522.69M |
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.05% | 0.94% | 1.06% | 0.98% | 1.11% | 0.98% | 1.06% | 1.09% | 1.03% | 0.92% | 1.20% | 1.00% | 1.13% | 1.02% | 1.01% | 1.03% |
Incyte's average Quarter revenue forecast for Dec 23 based on 8 analysts is $1.00B, with a low forecast of $971.32M, and a high forecast of $1.04B. INCY's average Quarter revenue forecast represents a 9.11% increase compared to the company's last Quarter revenue of $919.02M (Sep 23).
Incyte EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $260.65M | $193.78M | $63.84M | $121.08M | $144.69M | $258.27M | $124.18M | $135.63M | $224.60M | $186.45M | $83.52M | $181.70M | $9.98M | $320.46M | $-690.38M | $139.96M | $162.48M |
| Avg Forecast | $215.34M | $206.25M | $195.69M | $170.54M | $185.42M | $177.51M | $174.80M | $154.70M | $175.71M | $166.38M | $157.02M | $125.06M | $155.14M | $149.09M | $140.75M | $113.69M | $135.88M | $147.32M | $126.64M | $103.35M | $125.70M | $115.44M | $106.05M | $79.60M | $102.13M | $96.33M | $94.12M | $-4.16B | $88.97M | $82.77M |
| High Forecast | $217.66M | $208.47M | $197.80M | $172.38M | $187.42M | $179.43M | $176.69M | $156.37M | $177.61M | $180.25M | $158.71M | $150.07M | $161.23M | $154.57M | $142.27M | $136.42M | $137.35M | $176.78M | $132.00M | $124.02M | $131.02M | $120.32M | $110.53M | $95.52M | $106.46M | $100.41M | $98.10M | $-3.32B | $92.74M | $86.27M |
| Low Forecast | $211.41M | $202.49M | $192.12M | $167.43M | $182.04M | $174.28M | $171.62M | $151.88M | $172.51M | $163.30M | $154.16M | $100.04M | $150.28M | $145.59M | $138.18M | $90.95M | $133.41M | $117.86M | $123.74M | $82.68M | $122.82M | $112.79M | $103.62M | $63.68M | $99.80M | $94.13M | $91.96M | $-4.99B | $86.93M | $80.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75% | 1.38% | 0.56% | 0.89% | 0.98% | 2.04% | 1.20% | 1.08% | 1.95% | 1.76% | 1.05% | 1.78% | 0.10% | 3.40% | 0.17% | 1.57% | 1.96% |
8 analysts predict INCY's average Quarter EBITDA for Dec 23 to be $155.14M, with a high of $161.23M and a low of $150.28M. This is -40.48% lower than Incyte's previous annual EBITDA (Sep 23) of $260.65M.
Incyte Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $171.27M | $203.55M | $21.70M | $28.46M | $112.78M | $161.43M | $37.99M | $563.85M | $181.74M | $149.46M | $53.53M | $149.85M | $-15.20M | $290.30M | $-720.64M | $111.00M | $128.27M |
| Avg Forecast | $403.62M | $386.13M | $372.56M | $285.20M | $332.06M | $314.61M | $303.26M | $233.45M | $309.89M | $277.08M | $163.16M | $54.20M | $250.55M | $181.91M | $151.85M | $49.28M | $65.45M | $119.21M | $122.36M | $44.80M | $122.42M | $126.99M | $120.79M | $51.03M | $117.50M | $111.56M | $105.16M | $-4.34B | $77.61M | $96.77M |
| High Forecast | $409.28M | $391.54M | $377.78M | $289.20M | $336.72M | $319.02M | $307.52M | $236.72M | $314.24M | $381.75M | $165.44M | $65.04M | $277.47M | $215.79M | $153.98M | $59.13M | $66.37M | $143.05M | $129.09M | $53.76M | $129.15M | $133.97M | $127.43M | $61.23M | $123.96M | $117.69M | $110.94M | $-3.47B | $81.87M | $102.09M |
| Low Forecast | $394.06M | $376.98M | $363.73M | $278.44M | $324.19M | $307.15M | $296.08M | $227.92M | $302.55M | $178.56M | $159.29M | $43.36M | $225.71M | $112.35M | $148.25M | $39.42M | $63.90M | $95.37M | $118.72M | $35.84M | $118.77M | $123.21M | $117.19M | $40.82M | $114.00M | $108.24M | $102.03M | $-5.21B | $75.30M | $93.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 1.34% | 0.44% | 0.43% | 0.95% | 1.32% | 0.85% | 4.61% | 1.43% | 1.24% | 1.05% | 1.28% | -0.14% | 2.76% | 0.17% | 1.43% | 1.33% |
Incyte's average Quarter net income forecast for Dec 23 is $250.55M, with a range of $225.71M to $277.47M. INCY's average Quarter net income forecast represents a 46.29% increase compared to the company's last Quarter net income of $171.27M (Sep 23).
Incyte SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $267.89M | $283.93M | $315.61M | $272.82M | $266.50M | $253.28M | $209.58M | $226.20M | $190.70M | $168.90M | $153.80M | $167.00M | $120.80M | $118.00M | $113.28M | $136.18M | $102.61M |
| Avg Forecast | $352.97M | $338.07M | $320.77M | $279.54M | $303.93M | $290.97M | $286.53M | $253.58M | $288.02M | $272.72M | $257.38M | $299.04M | $254.30M | $244.39M | $230.71M | $271.85M | $222.74M | $125.09M | $207.58M | $247.14M | $206.05M | $189.22M | $173.83M | $146.59M | $167.41M | $157.91M | $154.28M | $141.02M | $145.84M | $135.67M |
| High Forecast | $356.78M | $341.71M | $324.22M | $282.56M | $307.21M | $294.11M | $289.62M | $256.31M | $291.12M | $295.45M | $260.15M | $358.85M | $264.28M | $253.36M | $233.20M | $326.23M | $225.14M | $150.10M | $216.36M | $296.57M | $214.76M | $197.22M | $181.18M | $175.91M | $174.50M | $164.59M | $160.80M | $146.99M | $152.01M | $141.41M |
| Low Forecast | $346.54M | $331.91M | $314.92M | $274.45M | $298.39M | $285.67M | $281.31M | $248.96M | $282.77M | $267.67M | $252.69M | $239.23M | $246.34M | $238.65M | $226.50M | $217.48M | $218.68M | $100.07M | $202.83M | $197.71M | $201.33M | $184.88M | $169.85M | $117.27M | $163.58M | $154.29M | $150.74M | $137.79M | $142.50M | $132.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.23% | 1.16% | 1.22% | 2.13% | 1.22% | 0.85% | 1.10% | 1.01% | 0.97% | 1.05% | 1.00% | 0.77% | 0.76% | 0.80% | 0.93% | 0.76% |
Incyte's average Quarter SG&A projection for Dec 23 is $254.30M, based on 8 Wall Street analysts, with a range of $246.34M to $264.28M. The forecast indicates a -5.07% fall compared to INCY last annual SG&A of $267.89M (Sep 23).
Incyte EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.76 | $0.91 | $0.10 | $0.13 | $0.51 | $0.73 | $0.17 | $2.55 | $0.82 | $0.68 | $0.24 | $0.68 | $-0.07 | $1.33 | $-3.33 | $0.51 | $0.60 |
| Avg Forecast | $1.85 | $1.77 | $1.71 | $1.31 | $1.52 | $1.44 | $1.39 | $1.07 | $1.42 | $1.27 | $0.75 | $0.78 | $1.15 | $0.83 | $0.70 | $0.56 | $0.30 | $0.50 | $0.56 | $0.46 | $0.56 | $0.58 | $0.55 | $0.45 | $0.54 | $0.51 | $0.48 | $0.35 | $0.36 | $0.44 |
| High Forecast | $1.88 | $1.79 | $1.73 | $1.33 | $1.54 | $1.46 | $1.41 | $1.08 | $1.44 | $1.75 | $0.76 | $0.79 | $1.27 | $0.99 | $0.71 | $0.57 | $0.30 | $0.51 | $0.59 | $0.48 | $0.59 | $0.61 | $0.58 | $0.48 | $0.57 | $0.54 | $0.51 | $0.37 | $0.38 | $0.47 |
| Low Forecast | $1.81 | $1.73 | $1.67 | $1.28 | $1.49 | $1.41 | $1.36 | $1.04 | $1.39 | $0.82 | $0.73 | $0.76 | $1.03 | $0.51 | $0.68 | $0.55 | $0.29 | $0.49 | $0.54 | $0.44 | $0.54 | $0.56 | $0.54 | $0.44 | $0.52 | $0.50 | $0.47 | $0.34 | $0.35 | $0.43 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.31% | 0.18% | 0.43% | 1.01% | 1.30% | 0.37% | 4.54% | 1.41% | 1.23% | 0.53% | 1.26% | -0.14% | 2.76% | -9.58% | 1.43% | 1.35% |
According to 8 Wall Street analysts, Incyte's projected average Quarter EPS for Dec 23 is $1.15, with a low estimate of $1.03 and a high estimate of $1.27. This represents a 51.11% increase compared to INCY previous annual EPS of $0.76 (Sep 23).
Incyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals | $21.49 | $45.38 | 111.17% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| ACAD | ACADIA Pharmaceuticals | $16.32 | $26.57 | 62.81% | Buy |
| SRPT | Sarepta Therapeutics | $124.65 | $169.93 | 36.33% | Buy |
| FOLD | Amicus Therapeutics | $11.30 | $15.33 | 35.66% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| HRMY | Harmony Biosciences | $38.91 | $50.67 | 30.22% | Buy |
| DNLI | Denali Therapeutics | $30.77 | $40.00 | 30.00% | Buy |
| INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
| AXSM | Axsome Therapeutics | $93.67 | $117.83 | 25.79% | Buy |
| BGNE | BeiGene | $198.49 | $247.75 | 24.82% | Buy |
| IONS | Ionis Pharmaceuticals | $42.19 | $50.84 | 20.50% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
| ARGX | argenx SE | $538.01 | $446.55 | -17.00% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |
INCY Forecast FAQ
Is Incyte a good buy?
Yes, according to 17 Wall Street analysts, Incyte (INCY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 58.82% of INCY's total ratings.
What is INCY's price target?
Incyte (INCY) average price target is $81 with a range of $48 to $136, implying a 27.44% from its last price of $63.56. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Incyte stock go up soon?
According to Wall Street analysts' prediction for INCY stock, the company can go up by 27.44% (from the last price of $63.56 to the average price target of $81), up by 113.97% based on the highest stock price target, and down by -24.48% based on the lowest stock price target.
Can Incyte stock reach $100?
INCY's highest twelve months analyst stock price target of $136 supports the claim that Incyte can reach $100 in the near future.
What is Incyte's current price target trend?
1 Wall Street analyst forecast a $92 price target for Incyte (INCY) this month, up 44.75% from its last price of $63.56. Compared to the last 3 and 12 months, the average price target increased by 12.89% and increased by 4.30%, respectively.
What are Incyte's analysts' financial forecasts?
Incyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.48B (high $4.52B, low $4.39B), average EBITDA is $692.44M (high $699.91M, low $679.82M), average net income is $1.18B (high $1.2B, low $1.16B), average SG&A $1.14B (high $1.15B, low $1.11B), and average EPS is $5.42 (high $5.5, low $5.3). INCY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.09B (high $5.15B, low $5B), average EBITDA is $787.82M (high $796.31M, low $773.46M), average net income is $1.45B (high $1.47B, low $1.41B), average SG&A $1.29B (high $1.31B, low $1.27B), and average EPS is $6.63 (high $6.73, low $6.48).
Did the INCY's actual financial results beat the analysts' financial forecasts?
Based on Incyte's last annual report (Dec 2022), the company's revenue was $3.39B, beating the average analysts forecast of $3.29B by 3.20%. Apple's EBITDA was $631.52M, beating the average prediction of $513.2M by 23.06%. The company's net income was $340.66M, missing the average estimation of $351.82M by -3.17%. Apple's SG&A was $1B, beating the average forecast of $802.54M by 24.87%. Lastly, the company's EPS was $1.53, missing the average prediction of $1.82 by -15.96%. In terms of the last quarterly report (Sep 2023), Incyte's revenue was $919.02M, missing the average analysts' forecast of $963.63M by -4.63%. The company's EBITDA was $260.65M, beating the average prediction of $149.09M by 74.82%. Incyte's net income was $171.27M, missing the average estimation of $181.91M by -5.85%. The company's SG&A was $267.89M, beating the average forecast of $244.39M by 9.62%. Lastly, the company's EPS was $0.76, missing the average prediction of $0.834 by -8.85%